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Infrequent CDKN2 (MTSJ/p16) gene alterations in human primary
breast cancer
EMJJ Berns',3, JGM Klijn', M Smid', IL van Staveren', NA Gruis2 and JA Foekens'
Division of'Endocrine Oncology (Department ofMedical Oncology), Dr Daniel den Hoed Cancer Center, Rotterdam and
2Department ofHuman Genetics, Leiden University, The Netherlands.
Summary Changes which lead to excessive cyclin production or to loss of cell cycle inhibition by proteins
such as pl6/MTSI may release breast tumour cells from the constraints of cell division. In order to establish
the frequency of MTSI/pl6 gene alteration and its relation with genetic damage to the p53 and cyclin Dl
genes, we have studied these gene abnormalities in 164 human primary breast cancers and in six breast cancer
cell lines. Two breast cancer cell lines and one primary tumour showed a homozygous deletion of exon 2 of
the MTSJ gene. Using single-strand conformation polymorphism and subsequent sequencing analysis, one
tumour showed an alteration at codon 67 (CCC-*CTC; Pro to Leu). Another tumour showed a mutation at
codon 98 (without amino acid change) with an additional polymorphism at codon 140. This polymorphism
was also found in 13 other tumour samples, but has no effect on (disease-free) survival. From these data we
conclude that the occurrence of CDKN2 (pl6/MTSl) mutation in primary breast cancer is a rare event and is
not likely to be involved in human breast tumour carcinogenesis and progression.
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An orderly sequence of kinase subunits (CDK4, CDK2 and
CDC2) expressed along with a succession of cyclins (D, E, A
and B) is necessary for the progression of the mammalian cell
cycle from G, to mitosis. Three major inhibitors of cyc-
lin-CDK complexes have been identified: p27, which is
induced by transforming growth factor beta (TGF-3) and by
cell-cell contact; p21 (WAF-1, CIPI, SDIl), which is trans-
criptionally activated by the tumour-suppressor gene p53w';
and p16, whose physiological inducers have not yet been
elucidated. While p21 reacts more broadly with CDKs
throughout the cell cycle, the inhibitor p27 interacts primarily
with D-type cyclins and CDK4, and to a lesser extent with
cyclin E and CDK2 complexes, and p16 specifically inhibits
cyclin D-CDK4 activation (pl6"4), (reviewed by Sherr,
1993; Peters, 1994; Hartwell and Kastan, 1994).
CDKN2 (pl6/MTSI) has been mapped to chromosome
9p2l, and its coding region encompasses three exons (Ser-
rano et al., 1993). This gene has been found to be
homozygously deleted or mutated at high frequency in cell
lines derived from tumours of brain, bone, bladder, skin,
kidney, lung, ovary and lymphocytes, and in 50-60% of the
breast cancer cell lines studied (Kamb et al., 1994; Okamoto
et al., 1994). Although the role of MTSJ in primary breast
cancer is unclear, it is of interest that cyclin Dl has been
reported to be abnormally expressed in one-third of the
breast cancers studied (Gillet et al., 1994) and that p53
mutations, which may lead to loss of p21 expression, have
been detected in 20-40% of human primary breast tumours
as well (Greenblatt et al., 1994). In the present analysis of
164 primary breast cancers and six breast cancer cell lines, we
aimed to assess (a) the frequency of CDKN2 (pl6/MTSI)
gene alterations and (b) the possible concurrent appearance
of genetic damage to the CDKN2 (pl6/MTSI), p53 and
cyclin Dl (llql3) genes.
Materials and methods
A total of 164 human primary breast tumour specimens and
six established breast cancer cell lines (MCF-7, MDA-MB-
231, T47-D, ZR75.1, SKBR-3, EVSA-T) were included in
this study. As a negative control, cultured human breast
fibroblasts were used. Thirty-five per cent of the patients
were premenopausal and 65% post-menopausal; 38% had no
involved lymph nodes, 31% had 1-3 nodes involved, 31%
had >3 nodes involved and the majority of the tumours
were <5cm (<2cm, 27%; 2-5cm, 57%); data on 144
patients were available). The breast tumour specimens were
stored in liquid nitrogen and DNA was isolated according to
procedures described previously (Berns et al., 1992a).
Exon 2, which covers 69% of the coding region of the
MTSI gene, has been described to contain the majority of
mutations. We have analysed exon 2 by single-strand
conformation polymorphism analysis (SSCP; Orita et al.,
1989) followed by sequencing of altered PCR products. In
brief, exon 2 was amplified by PCR with intronic primer
pairs identified from the genomic sequence (Serrano et al.,
1993); upstream Mu 5'-GAGAACTCAAGAAGGAAAT-
TGG-3' and downstream Md 5'-TCTGAGCTTTGGAAG-
CTCTCA-3' generating a 522 bp fragment). Amplification
was performed in a DNA thermal cycler 480 (Perkin-Elmer
Cetus, Norwalk, CT, USA) for 30 cycles. To identify gene
deletions, DNA-PCR product ratios were compared to
minimise non-tumour cell contamination. PCR product was
diluted and reamplified, in the presence of[32P]dATP, by two
sets of nested primers - Au 5'-AGCTTCCTTTCCGT-
CATGC/Ad 5'-ACCACCAGCGTGTCCAGGAAG-3' gen-
erating a product of 198 bp (fragment A) and Bu 5'-ACT-
CTCACCCGACCCGTG-3'/Md, generating a product of
281 bp (fragment B). Before loading, PCR product 'B' was
digested with KpnI, making products below 200 bp. This step
reduces the false-negative detection rate to below 10%
(Hayashi and Yandell, 1993).
Following SSCP on a 8% polyacrylamide gel containing
10% (v/v) glycerol at 30 W for 6 h, products with an altered
electrophoretic mobility of single-stranded nucleic acids were
analysed again and then sequenced. To this end, PCR prod-
ucts were subcloned into a TA cloning vector (TA cloning
kit, Invitrogen), sequenced using a T7 sequencing Kit
(Pharmacia) and electrophoresed on a 6% denaturing poly-
acrylamide gel containing 8 M urea. Mutations in the p53
gene were studied by PCR-SSCP using primer panels each
flanking the exons 5, 6, 7 and 8 (Clontech, USA). Amplifi-
cation of the amplicon containing the cyclin Dl gene on
1 1q13 was studied by Southern blotting as described
previously (Bemns et al., 1992b).
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Results
A total of 16 (10%) of the 164 breast primary tumours
studied had an alteration in the MTSI gene (exon 2). For
one tumour sample no MTSJ (exon 2) PCR product could
be obtained (after repetitive runs of PCR, with different
primers). Southern blotting analysis revealed a faint band,
probably due to contaminating normal (stromal) cells (not
shown). Control reactions (with primers for exons 5-8 of the
p53 gene) confirmed the integrity of the DNA samples. These
results suggest a homozygous deletion of or near exon 2 of
the CDKN2 (pl6/MTSI) gene. Of the six breast cancer cell
lines studied, two (MCF-7, MDA-MB-231) showed a homo-
zygous deletion of the CDKN2 (pl6/MTSI) gene. The other
15 primary tumours showed altered migration patterns on
SSCP (representative examples are shown in Figure la).
After sequence analysis one tumour was shown to have a
mutation at codon 67 (CCC-+CTC; Pro to Leu); the other
tumour had a mutation at codon 98, not resulting in an
amino acid change, and had an additional change at codon
140. In the remaining 13 tumour samples a base pair change
at codon 140 was observed also (Figure lb and Table I). This
variant has been shown to be a common polymorphism (Ala
to Thr) (Cairns et al., 1994). This change creates a Sst2
restriction fragment length polymorphism, which facilitates
screening (data not shown). We next studied whether this
polymorphism may be related to breast cancer prognosis.
However, Kaplan-Meier analysis showed no difference in
disease-free or overall survival between patients with or with-
out this gene alteration (not shown).
Forty per cent of the primary breast tumours used in this
study showed a mutation of the p53 gene and 16% showed
an amplification of the 11q13 locus. Of the two breast cancer
samples shown to have a mutation in the CDKN2 (pl6/
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MTSI) gene, each had a mutated p53 gene (exon 7 and 6
respectively), while the lql3 locus was not affected (Table
I). The tumour showing a homozygous deletion of the
CDKN2 (p16/MTSI) gene did not have a mutated p53 gene
or amplification of the amplicon at 11q13. Of the 13 primary
breast cancer samples showing only a polymorphism (codon
140) in exon 2 of the CDKN2 (p16/MTSI) gene (Table I),
two had a mutation in the p53 gene (in exons 6 + 8 and in
exon 7 respectively), both accompanied by an additional
amplification of 1 1q13. The remaining 11 tumours with a
polymorphism in exon 2 of the CDKN2 (p16/MTSI) gene
had no mutation in the p53 gene, whereas three had an
amplified amplicon at lql3 (Table I).
Discussion
CDKN2 (p16/MTSI) acts primarily during the GI to S tran-
sition by binding to CDK4 and thereby inhibiting the
catalytic activity of the CDK4-cyclin D complex (Serrano et
al., 1993). Although this gene has been shown to be
homozygously deleted in human breast cancer cell lines at
high frequency (Kamb et al., 1994), loss of heterozygosity
(LOH), thought to reveal recessive mutations in tumour-
suppressor genes located within the affected region, on
chromosome arm 9p has not yet been described in human
primary breast cancer (Smith et al., 1993). LOH has been
described in human breast cancer at several chromosomal
arms (including lp/q, 3p, 6q, 7p/q, lip, 13q, 16q, 17p/q,
18p/q, 22q; Callahan et al., 1993; Smith et al., 1993), with
frequently lost regions being at 3p, 6q, 7p, 16q, 17p
(40-60%) and less frequently affected areas being lp/q, Ilp,
13q, 18p/q, 22q (15-20%), with a baseline of detection of
LOH of approximately 5%.
N
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Figure 1 Single-strand conformation polymorphism assay (a) and sequence analysis (b) of the CDKN2 (pl6/MTSJ) gene (exon 2)
in human primary breast cancer. (a) SSCP gels were run as described in the Materials and methods section. The asterisk indicates
altered migration patterns. (N)D, (not) denatured. (b) DNA sequence analysis of PCR products with altered patterns as compared
with control sequences. Each sequence is shown 5' (bottom) to 3' (top). The base changes have been indicated by an asterisk and
the codon changes are depicted next to the lanes. Numbers, on top, represent patient numbers from Table I.CDKN2genealterations in primary breast cancer
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Table I
CDKN2 (p16/MTSI) alterationa p53 mutationb Amplificationc
Case Nucleotide change Codon Amino acid Wt/M Exon 1Iq13
2252 CCC---> CTC 67 Pro---> Leu M 7 N
2908 GTG--->GTA 98 Val---> Val M 6 N
GCG---> ACG 140 Ala---> Thr
2122 GCG--->ACG 140 Ala---> Thr Wt N
2159 GCG---> ACG 140 Ala ---> Thr Wt N
2225 GCG ---> ACG 140 Ala ---> Thr Wt A (5)
2241 GCG---> ACG 140 Ala---> Thr Wt N
2256 GCG---> ACG 140 Ala---> Thr Wt N
2278 GCG--->ACG 140 Ala---> Thr Wt N
2298 GCG---> ACG 140 Ala---> Thr Wt N
2323 GCG---> ACG 140 Ala---> Thr Wt N
2324 GCG ---> ACG 140 Ala ---> Thr M 6/8 A (4)
2326 GCG ---> ACG 140 Ala ---> Thr Wt A (8)
2337 GCG---> ACG 140 Ala ---> Thr Wt A (4)
2338 GCG---> ACG 140 Ala---> Thr Wt N
2593 GCG--->ACG 140 Ala ---> Thr M 7 A (4)
2151 Deletion Wt N
aCDKN2(p16/MTSI) (exon 2) gene alteration sequenced as described in the Materials
and methods section. The polymorphism (codon 140) in exon 2 creates a Sst2 restriction
site which facilitates screening. bp53 mutations were analysed with PCR-SSCP ofexons
5-8,asdescribedintheMaterialsandmethodssection.cAmplified (A), referstogenecopy
numbers >2 (gene copy number in parentheses). Wt and M; wild-type and mutated form
of p53 respectively.
Using PCR-SSCP and sequencing analysis of the CDKN2
(pI6/MTSI) gene (exon 2) in a total of 164 primary breast
cancers, we observed only two mutations, a prevalent
polymorphism at codon 140 (Ala to Thr), which is common
in the population (Cairns et al., 1994), and one putative
homozygous deletion. These data are in agreement with the
results published by Xu et al. (1994), who analysed all three
exons and observed no mutations in this gene, although they
did find a neutral polymorphism (at bp 494) in the 3' un-
translated region in a smaller group of 37 primary breast
tumours studied. Moreover, data on different types of
primary cancers by other authors suggest that the frequency
of CDKN2 (pl6/MTSI) gene mutation in some types of
cancer (for example lung, bladder, kidney, head and neck,
brain, colon; Cairns et al., 1994; Okamoto et al., 1994) is also
quite low. However, this may not be true for all types of
primary cancer since mutations of the CDKN2 (pl6/MTSI)
gene were detected in 52% of Japanese oesophageal carc-
inomas (Mori et al., 1994) and in 16 out of 64 human
primary non-small-cell lung carcinomas examined (Hayashi
et al., 1994) whereas homozygous deletions, without muta-
tions, occur in 22% of malignant mesotheliomas (Cheng et
al., 1994).
In conclusion, the role of CDKN2 (pl6/MTSI) in human
cancer is still controversial, and our data on primary breast
cancer, together with the fact that LOH on 9p is a rare event,
raise the possibility that CDKN2 (pl6/MTSI) deletions and/
or mutations are more frequent in breast cancer cell lines
than in human primary breast cancer and that this gene plays
no important role in human breast tumorigenesis and prog-
ression. The low incidence of CDKN2 (pl6/MTSI) gene
mutations does not allow for the study of an association with
p53 gene mutations or cyclin DI amplification or overexpres-
sion.
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